Imclone--hier hilft wohl nur ein Call

siehe posting 69, GS8PWT.
oder:
www.goldman-sachs.de/SID1090407767.0/...nverstanden&xCookies=0

ich finde, sie sehen ziemlich gut aus. erbitux umsatz im Q bei >70 mio $, profit gut etc. nur die aussicht "wir werden das jahr positiv abschliessen" verunsichert mich ein bisschen. sollte nämlich gar keine frage sein..
aktie daraufhin etwas runter bei uns..

ir.thomsonfn.com/InvestorRelations/...roduct=IR&storyid=117626

goldman nimmt den spread hoch und sperrt mal wieder..
hinweis : wer z.b. bei consors ist, kann von denen bei goldman anrufen lassen und bekommt trotzdem preise. im mom für GS8PWT z.b. 0,28-33 (man beachte, dass sie jetzt den spread auf FÜNF cent ausgeweitet haben !).
ich fang wieder an zu kaufen, auch wenns wahrscheinlich bissi früh ist  (von wegen "never catch a falling knife" und so).
aber bei 51 und 60 verkauft (siehe oben) muss ich einfach bei 33 wieder rein. zumindest für ne anfangsposition. der nachmittag/abend wird spannend !!

Sell on good News!?



ImClone veröffentlicht Gewinn des zweiten Quartals  
21.07.2004 13:07:00


   
Das US-amerikanische Biotechnologieunternehmen ImClone Systems Inc. hat im zweiten Quartal einen Gewinn ausgewiesen. Wie das Unternehmen am Mittwoch mitteilte, ist dieser Gewinn auf den sehr guten Absatz des Präparats Erbitux zurückzuführen.
Der Nettogewinn hat bei 24 Mio. Dollar bzw. 29 Cents je Aktie gelegen. Im gleichen Zeitraum des Vorjahres hatte ImClone einen Verlust in Höhe von 34,8 Mio. Dollar bzw. 47 Cents ausgewiesen. Die Analysten waren für das zweite Quartal 2004 von einem Gewinn je Aktie in Höhe von 25 Cents ausgegangen und sehen ihn im nächsten Quartal bei 29 Cents.

Ferner hat das Unternehmen bekannt gegeben, dass der Umsatz bei 71,54 Mio. Dollar gelegen hat, was eine deutliche Steigerung zum Vorjahreswert von 17,88 Mio. Dollar darstellt. Er war von den Analysten auf 64,14 Mio. Dollar veranschlagt worden. Im nächsten Quartal wird er ihrer Ansicht nach bei 73,33 Mio. Dollar liegen.

Die Aktie schloss gestern an der NASDAQ bei 80,73 Dollar.
 

also "kaufen wenn die kanonen donnern"... (zitat F.Busch)

um 11 a.m. eastern time (müsste so 21.uhr bei uns sein) kommt, wie immer, die präsentation. kann man auf deren web-site verfolgen.vielleicht hilft ja das dann. hab noch mehr gekauft.

du mußt noch ruhiger werden, wenn du am Termingeschäft Geld verdienen willst!

hatte die scheine mit 50 % plus verkauft, und kaufe sie jetzt (fast halbiert) wieder. das halte ich nicht für "nervös", sondern für (bisher! gelungenes) kurzfristiges traiding. und nun warte ich auf die präsentation.
alles im lack !!  

das Ebitux nicht gut läuft......


Gruß Pichel

auch wenn die fakten des Q2 (für mich) nix dergleichen aussagen :
71 mio erbitux-umsatz im ersten vollständigen quartal, gewinn höher als von analysten erwartet, royal revenues höher als erwartet. das medikament ist der knaller. gestern die aktie hoch gemacht, weil die zulassung für andere krebsarten beantragt werden wird. heute alles vergessen..

also abwarten, was nachher passiert.

RV (Relative Value): RV is an indicator of long-term price appreciation potential. IMCL has an RV of 1.26, which is very good on a scale of 0.00 to 2.00. This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00.
 
RS (Relative Safety): RS is an indicator of risk. IMCL has an RS rating of 0.71, which is poor on a scale of 0.00 to 2.00. RS is computed from an analysis of the consistency and predictability of a company's financial performance, debt to equity ratio, sales volume, business longevity, price volatility and other factors. A stock with an RS rating greater than 1.00 is safer and more predictable than the average stock in the VectorVest database. VectorVest favors the purchase of stocks of companies with consistent, predictable financial performance.
 
RT (Relative Timing): RT is a fast, smart, accurate indicator of a stock's price trend. IMCL has a Relative Timing rating of 1.17, which is good on a scale of 0.00 to 2.00.  RT is computed from an analysis of the direction, magnitude, and dynamics of a stock's price movements over one day, one week, one quarter and one year time periods. Once a stock's price has established a strong trend, it is expected to continue in that trend for the short-term. If a trend dissipates, RT will gravitate toward 1.00. RT will explode from bottoms, dive from tops, and reflect changes in price momentum. VectorVest favors the purchase of stocks with RT ratings above 1.00.  
 
VST (VST-Vector):  VST is the master indicator for ranking every stock in the VectorVest database. IMCL has a VST rating of 1.07, which is fair on a scale of 0.00 to 2.00. VST is computed from the square root of a weighted sum of the squares of RV, RS, and RT. Stocks with the highest VST ratings have the best combinations of Value, Safety and Timing. These are the stocks to own for above average, long-term capital appreciation. VectorVest advocates the purchase of safe, undervalued stocks rising in price. The efficacy of this indicator was demonstrated in a study conducted at the University of Chicago which showed that high VST stocks outperformed the S&P 500 by 583.1% over the six year period from 1996 through 2002.  
 
CI (Comfort Index): CI is an indicator which reflects a stock's ability to resist severe and/or lengthy price declines. IMCL has a CI rating of 0.84, which is poor on a scale of 0.00 to 2.00. CI is quite different from RS in that it is based solely upon a stock's long-term price history. VectorVest advocates the purchase of high CI stocks.  
 
GRT (Earnings Growth Rate): GRT reflects a company's one to three year forecasted earnings growth rate in percent per year. IMCL has a forcasted Earnings Growth Rate of 39.00%, which VectorVest considers to be excellent. GRT is computed from historical, current and forecasted earnings data. It is updated each week for every stock in the VectorVest database. GRT often foretells a stock's future price trend. If a stock's GRT trend is upward, the stock's price will likely rise. If GRT is trending downward, the stock's Price will probably fall. VectorVest favors the purchase of stocks whose GRT is rising and is greater than the sum of current inflation and interest rates, (9.21%).  
 
Recommendation (REC): VectorVest gives a Buy, Sell, Hold recommendation on every stock, every day. IMCL has a Buy recommendation. REC reflects the cumulative effect of all the VectorVest parameters working together. These parameters are designed to help investors buy safe, undervalued stocks rising in price. They also help investors avoid or sell risky, overvalued stocks falling in price. VectorVest recommends that investors buy high VST-Vector, Buy-rated stocks in rising markets.  
 
Stop (Stop-Price): Stop is an indicator of when to sell a long position or cover a short position.  IMCL has a Stop of $74.40 per share. This is $6.33 below IMCL's current closing Price. A stock's Stop is computed from a 13 week moving average of its closing prices, and is fine-tuned according to the stock's fundamentals. High RV, high RS stocks have lower Stops, and low RV, low RS stocks have higher Stops. In the VectorVest system, a stock gets a 'B' or 'H' recommendation if its Price is above its Stop and an 'S' recommendation if its Price is below its Stop.
 
EPS (Earnings per Share):  EPS stands for leading 12 months Earnings Per Share.  IMCL has a forecasted EPS of $1.92 per share. VectorVest determines this forecast from a combination of recent earnings performance and traditional fiscal and/or calendar year earnings forecasts.  
 
P/E (Price to Earnings Ratio): P/E is a popular measure of stock valuation which shows the dollars required to buy one dollar of earnings.  IMCL has a P/E of 42.05. This ratio may be deemed to be high or low depending upon your frame of reference. The average P/E of all the stocks in the VectorVest database is 30.61. P/E is computed daily using the formula: P/E = Price/EPS.  
 
EY (Earnings Yield): EY reflects earnings per share as a percent of Price. EY is related to P/E via the formula, EY = 100 / (P/E), and may be used in place of P/E as a measure of valuation. EY has the advantages that it is always determinate and can reflect negative earnings. IMCL has an EY of 2.38 percent. This is below the current average of 3.25% for all the stocks in the VectorVest database. EY equals 100 x (EPS/Price).  
 
GPE (Growth to P/E Ratio): GPE is another popular measure of stock valuation. It compares earnings growth rate to P/E ratio. IMCL has a GPE rating of 0.93.  High growth stocks are believed to be able to justify high P/E ratios. A stock is commonly considered to be undervalued when GPE is greater than 1.00 and overvalued when GPE is below 1.00. Unfortunately, this rule of thumb does not take into account the effect of interest rates on P/E ratios. The operative GPE ratio of 1.00 is valid when and only when interest rates equal 10%. With long-term interest rates currently at 5.91%, the operative GPE ratio is 0.35. Therefore, IMCL may be considered to be undervalued.  
 
DIV (Dividend): VectorVest reports annual, regular, cash dividends as indicated by the most recent payments. Special distributions, one-time payments, stock dividends, etc., are not generally included in DIV. IMCL does not pay a dividend.  
 
DY (Dividend Yield): DY reflects earnings per share as a percent of Price. IMCL does not pay a dividend, so it does not have a Dividend Yield rating. . DY equals 100 x (DIV/Price). It is useful to compare DY with EY. If DY is not significantly lower than EY, the dividend payment may be in jeopardy.  
 
DS (Dividend Safety): DS is an indicator of the assurance that regular cash dividends will be declared and paid at current or at higher rates for the foreseeable future. IMCL does not pay a dividend, so it does not have a Dividend Safety rating . Stocks with DS values above 75 typically have RS values well above 1.00 and EY levels that are much higher than DY.

 
DG (Dividend Growth Rate): Dividend Growth is a subtle yet important indicator of a company's financial performance. It also provides some insight into the board's outlook on the company's ability to increase earnings. IMCL does not pay a dividend, so it does not have a Dividend Growth rating .  
 
YSG (YSG-Vector): YSG is an indicator which combines DIV, DY and DG into a single value, and allows direct comparison of all dividend-paying stocks in the database. IMCL does not pay a dividend, so it does not have a YSG rating . Stocks with the highest YSG values have the best combinations of Dividend Yield, Safety and Growth. These are the stocks to buy for above average current income and long-term growth.  
 
Open: IMCL opened trading at a price of $78.01 per share on 7/20/2004.
 
High: IMCL traded at a High price of $81.43 per share on 7/20/2004.
 
Low: IMCL traded at a Low price of $77.55 per share on 7/20/2004
 
Close: IMCL closed trading at price $80.73 per share on 7/20/2004. (Close is also called Price in the VectorVest system)
 
Range: Range reflects the difference between the High and Low prices for the day. IMCL traded with a range of $3.88 per share on 7/20/2004.  
 
$Change: IMCL closed up 3.97 from the prior day's closing Price.  
 
%PRC: IMCL's Price changed 5.17% from the prior day's closing price.
 
Volume: IMCL traded 4,207,000 shares on 7/20/2004.
 
AvgVol: AvgVol is the 50 day moving average of daily volume as computed by VectorVest. IMCL has an AvgVol of 3,253,900 shares traded per day.
 
%Vol: %Vol reflects the percent change in today's trading volume as compared to the AvgVol. %Vol equals 100 x (Volume/AvgVol). IMCL had a %Vol of 29.29% on 7/20/2004
 
Sales: IMCL has annual sales of $170,000,000
 
Sales Growth: Sales Growth is the Sales Growth Rate in percent over the last 12 months. IMCL has a Sales Growth of 460.00% per year. This is excellent. Sales Growth is updated each week for every stock. It is often useful to compare Sales Growth to Earnings Growth to gain an insight into a company's operations.  
 
Sales Per Share (SPS): IMCL has annual sales of $2.26 per share. SPS can be used as a measure of valuation when comparing stocks within an Industry Group.  
 
Price to Sales Ratio (P/S): IMCL has a P/S of 35.71. This ratio is also used as a measure of valuation. Here, too, it is useful when comparing stocks within an Industry Group.
 
Shares: IMCL has 75,000,000 shares of stock outstanding.
 
Market Capitalization: IMCL has a Market Capitalization of $6,102,000,000. Market Capitalization is calculated by multiplying price times shares outstanding.
 
Industry Group: IMCL has been assigned to the Drug (Biomedical\Genetic) Industry Group. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
 
Business Sector: IMCL has been assigned to the Drug Business Sector. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
 

heute von otperform auf marketperform

das wird den Kursrutsch ausmachen

Dagenen aktuell credit Suisse First Boston

21.07.2004
Imclone "outperform"
Credit Suisse First Boston

Rating-Update:

Die Analysten von Credit Suisse Fist Boston stufen die Aktie von ImClone Systems (ISIN US45245W1099/ WKN 883074) in einer Ersteinschätzung mit "outperform" ein. Das Kursziel liege bei 105 USD.



so unterschiedlich sind die Ratings
genauer Wortlaut muß ich noch suchen

- ImClone und Bristol-Myers Squibb wollen weitere

Zulassung für Erbitux heutige Meldung

doch leider finde ich mehr nicht dazu

neck cancer. dann wäre übrigens auch eine weitere milestone-zahlung von 350 mio $ (!!) fällig, studien waren extrem positiv, zulassung wird also kommen, wird aber noch dauern.

ImClone - Downgrade

(©GodmodeTrader - www.godmode-trader.de/)


Friedman Billings Ramsey haben heute die Aktie des Biotechnologie-Unternehmens ImClone von "buy" auf "neutral" abgestuft. Das Kursziel wurde von 93 auf 75 Dollar zurückgenommen.

Wie das Investmenthaus ausführte, hätten die Umsätze des Krebsmedikaments Erbitux im abgelaufenen Quartal bei 71 statt der prognostizierten 75 Millionen Dollar gelegen. Zudem werde die FDA-Zulassung für die Ausweitung des Einsatzes auf andere Krebsarten eher für das erste Halbjahr 2005 als für Ende 2004 erwartet. Der Einfluss dessen auf die Gewinnentwicklung sei zwar nicht sonderlich groß. Der Aktienkurs werde im Biotech-Sektor durch derartige Meldungen in der Regel aber nun einmal in Mitleidenschaft gezogen.

ImClone brechen in den USA um aktuell 18,01 Prozent auf 18,01 Prozent ein. :-))

umsatz und eps lagen über dem schnitt der analystenschätzungen, auch wenn friedmanBR mehr erwartet hatte.
VOR der asco, da war noch gar keine rede von erbitux für head und neck cancer, war die aktie übrigens 75 $, gegen 65 im mom. danach kamen die 250 mio milestone zahlung an sie, und 71 mio quartalsumsatz mit einem neuen medikament.
sorry, ich weiss auch, dass der markt immer recht hat, aber da fehlt mir das verständnis. ich bleib drin, hab immer weiter gekauft auf dem weg nach unten, und melde morgen dann konkurs an wenns weiter abwärts geht.
ps:hätte ich mal auf meine eigene warnung gehört (oben #80), von wegen "falling knife" und so. nahe tageslow geschlossen klingt auch nicht so toll (vor allem bei DEM umsatz). na ja, "die hoffnung stirbt zuletzt" !!  

Ich denke heute kommt die Gegenbewegung!
In USA!

gruß
gs

2. ImClone Systems (Nasdaq: IMCL) said that revenue surged almost 300 percent
during its second quarter to $71.5 million. The biotechnology firm collected 29
cents per share during the reporting period, topping Wall Street's expectations
by three cents and easing past its year-ago loss of 47 cents per share. Sales of
the firm's flagship drug, Erbitux, totaled $71.4 million. Investors must have
deduced something negative from the firm's report, as the stock has lost almost
18 percent today, plunging through its 20-week moving average for the first time
in more than six months.

Short sellers missed the boat on this potential profitable venture. As of the
last reporting period, there were eight million IMCL shares sold short, which
amounts to a short-interest ratio of less than two days to cover. Options
players also failed to take a stand for or against IMCL. The stock's SOIR
currently stands at 0.45, which is in the 52nd annual percentile. A slew of IMCL
options are active today, most notably in the August call series. The hefty
volume readings, especially on the August 75 and 80 strikes, will likely have an
effect on the stock's SOIR tomorrow morning.

Click the following link to see the Weekly Chart of IMCL Since February 2003
With 10-Week and 20-Week Moving Averages:
www.schaeffersresearch.com/wire?ID=10643  

Quelle Schaefers Cincenati

Quelle


Gruß Pichel

A randomized, international phase III trial (IMCL-9815) conducted by ImClone Systems and Merck KGaA presented at the American Society of Clinical Oncology (ASCO) annual meeting in June examining the impact of combining ERBITUX with radiation on locoregional control and overall survival in 424 patients with locally advanced SCCHN, and

--
A multicenter phase II trial (EMR-016) conducted by Merck KGaA presented at the ASCO annual meeting in June evaluating the response rate of ERBITUX as a single agent in 103 patients with advanced recurrent and/or metastatic SCCHN not suitable for further local therapy and who have failed platinum-based chemotherapy.

" Patients with this disease have been without any significantadvancements in approved treatments for over a decade," stated DanielS. Lynch, Chief Executive Officer of ImClone Systems. " We were pleasedto be able to present clinical trial data in head and neck cancer atthis year´s ASCO annual meeting, including the late-breaking Phase IIIstudy IMCL-9815. We look forward to working diligently with ourpartners to assemble and analyze all the data from the studies thatwill comprise this submission."
" Delivering to patients novel approaches to the treatment ofcancer is part of Bristol-Myers Squibb´s legacy and aligns with ourcomprehensive strategy to focus on areas of significant medical need,in this case the treatment of head and neck cancer," said Andrew G.Bodnar, M.D., Senior Vice President Strategy and Medical & ExternalAffairs, Bristol-Myers Squibb. " We will continue to work with ourpartners to conduct a thorough clinical development program to explorethe use of ERBITUX in various tumor types."

About Head and Neck Cancer

According to the American Cancer Society, approximately 40,000Americans will be diagnosed with oral, head and neck cancer this year,including cancers of the tongue, mouth, pharynx, and larynx. More than11,000 will die from the disease in 2004.

About ERBITUX(TM) (Cetuximab)

ERBITUX is approved by the FDA for use in combination withirinotecan in the treatment of patients with EGFR-expressing,metastatic colorectal cancer who are refractory to irinotecan-basedchemotherapy and for use as a single agent in the treatment ofpatients with EGFR-expressing, metastatic colorectal cancer who areintolerant to irinotecan-based chemotherapy. The effectiveness ofERBITUX for the treatment of colorectal cancer is based on objectiveresponse rates. Currently, no data are available that demonstrate animprovement in disease-related symptoms or increased survival withERBITUX.
ERBITUX binds specifically to epidermal growth factor receptor(EGFR, HER1, c-ErbB-1) on both normal and tumor cells, andcompetitively inhibits the binding of epidermal growth factor (EGF)and other ligands, such as transforming growth factor-alpha. The EGFRis constitutively expressed in many normal epithelial tissues,including the skin and hair follicle. Over-expression of EGFR is alsodetected in many human cancers including those of the colon andrectum.

ERBITUX Important Safety Information

Severe infusion reactions, rarely fatal and characterized by rapidonset of airway obstruction (bronchospasm, stridor, hoarseness),urticaria, and hypotension, have occurred in approximately 3% ofpatients with the administration of ERBITUX (Cetuximab). Mostreactions (90%) were associated with the first infusion of ERBITUX.Caution must be exercised with every ERBITUX infusion as there werepatients who experienced their first severe infusion reaction duringlater infusions.
Severe cases of interstitial lung disease (ILD), which was fatalin one case, occurred in less than 0.5% of patients receiving ERBITUX.
Dermatologic toxicities, including acneform rash (11% grade 3/4),skin drying and fissuring, inflammatory or infectious sequelae (e.g.blepharitis, cheilitis, cellulitis, cyst) and paronychial inflammation(0.4% grade 3) were reported. Sun exposure may exacerbate theseeffects.
Other serious adverse events associated with ERBITUX in clinicaltrials were fever (5%), sepsis (3%), kidney failure (2%), pulmonaryembolus (1%), dehydration (5% in patients receiving ERBITUX plusirinotecan, 2% receiving monotherapy) and diarrhea (6% in patientsreceiving ERBITUX plus irinotecan, 0.2% with monotherapy).
Additional common adverse events seen in patients receivingERBITUX plus irinotecan (n=354) or ERBITUX monotherapy (n=420) wereacneform rash (88%/90%), asthenia/malaise (73%/48%), diarrhea(72%/25%), nausea (55%/29%), abdominal pain (45%/26%), vomiting(41%/25%), fever (34%/27%), constipation (30%/26%) and headache(14%/26%).
Full prescribing information is available upon request, or atwww.ERBITUX.com.

About ImClone Systems Incorporated

ImClone Systems Incorporated is committed to advancing oncologycare by developing and commercializing a portfolio of targetedbiologic treatments designed to address the medical needs of patientswith a variety of cancers. The Company´s three programs include growthfactor blockers, angiogenesis inhibitors and cancer vaccines. ImCloneSystems´ strategy is to become a fully integrated biopharmaceuticalcompany, taking its development programs from the research stage tothe market. ImClone Systems´ headquarters and research operations arelocated in New York City, with additional administration andmanufacturing facilities in Branchburg, New Jersey.

Certain matters discussed in this news release may constituteforward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995 and the Federal securitieslaws. Although the company believes that the expectations reflected insuch forward-looking statements are based upon reasonable assumptionsit can give no assurance that its expectations will be achieved.Forward-looking information is subject to certain risks, trends anduncertainties that could cause actual results to differ materiallyfrom those projected. Many of these factors are beyond the company´sability to control or predict. Specifically there can be no guaranteethat the sBLA referenced above will be filed, or if filed, will befiled within the timeframe discussed above or that it will be approvedby the FDA. Important factors that may cause actual results to differmaterially and could impact the company and the statements containedin this news release can be found in the company´s filings with theSecurities and Exchange Commission including quarterly reports on Form10-Q, current reports on Form 8-K and annual reports on Form 10-K. Forforward-looking statements in this news release, the company claimsthe protection of the safe harbor for forward-looking statementscontained in the Private Securities Litigation Reform Act of 1995. Thecompany assumes no obligation to update or supplement anyforward-looking statements whether as a result of new information,future events or otherwise.

About Bristol-Myers Squibb

Bristol-Myers Squibb is dedicated to the discovery, developmentand exhaustive exploration of innovative cancer fighting therapiesdesigned to extend and enhance the lives of patients living withcancer. More than 40 years ago, Bristol-Myers Squibb built a unifiedvision for the future of cancer treatment. With expertise, dedicationand resolve, that vision led to the development of a diverse globalportfolio of anti-cancer therapies that are an important cornerstoneof care today. Hundreds of scientists at Bristol-Myers Squibb´sPharmaceutical Research Institute are studying ways to improve currentcancer treatments and identify better, more effective medicines forthe future.
Bristol-Myers Squibb is a global pharmaceutical and related healthcare products company whose mission is to extend and enhance humanlife.

This press release contains " forward-looking statements" as thatterm is defined in the Private Securities Litigation Reform Act of1995. Such forward-looking statements are based on currentexpectations and involve inherent risks and uncertainties, includingfactors that could delay, divert or change any of them, and couldcause actual outcomes and results to differ materially from currentexpectations. No forward-looking statement can be guaranteed.Specifically there can be no guarantee that the sBLA referenced abovewill be filed, or if filed, will be filed within the timeframediscussed above or that it will be approved by the FDA.Forward-looking statements in this press release should be evaluatedtogether with the many uncertainties that affect Bristol-MyersSquibb´s business, particularly those identified in the cautionaryfactors discussion in Bristol-Myers Squibb´s Annual Report on Form10-K for the year ended December 31, 2003 and in our Quarterly Reportson Form 10-Q. Bristol-Myers Squibb undertakes no obligation topublicly update any forward-looking statement, whether as a result ofnew information, future events or otherwise.

--30--ML/ny* CONTACT: Media and Investor Contacts: ImClone Systems Incorporated Andrea Rabney, 646-638-5058 andrea.rabney@imclone.com or David Pitts, 646-638-5058 david.pitts@imclone.com or Investor Relations: Stefania Bethlen, 646-638-5058 stefania.bethlen@imclone.com or Bristol-Myers Squibb Tracy Furey, 609-252-3208 tracy.furey@bms.com or Kathy Baum, 609-252-4227 kathy.baum@bms.com or Investor Relations: Bristol-Myers Squibb Susan Walser, 212-546-4631 susan.walser@bms.com or John Elicker, 212-546-3775 john.elicker@bms.com KEYWORD: NEW YORK NEW JERSEY INDUSTRY KEYWORD: MANUFACTURING PHARMACEUTICAL MEDICALBIOTECHNOLOGY SOURCE: ImClone Systems Incorporated

(c) 2004 Business Wire. All reproduction, other than for an individual user's reference, is prohibited without prior written permiss

würg !!